TON - March 2017, Vol 10, No 2

Surviving cancer is the start of a new journey for many individuals. Cancer survivors face a multitude of challenges, including prevention of new and recurrent cancers; interventions for illnesses secondary to cancer and its treatment; concerns related to employment, insurance, and disability; and coordination between specialists and primary care providers. Read More ›

Noteworthy Numbers: Thyroid Cancer
Thyroid cancer represents only 3.8% of new cancer cases annually in the United States, but occurs approximately 3 times as often in women as in men. Read More ›

What to expect in this month's issue of The Oncology Nurse APN/PA Read More ›

A Direct Access Screening Colonoscopy (DASC) program at Advocate Illinois Masonic Medical Center in Chicago was found to increase the overall screening rate for colorectal cancer (CRC) by almost 100% without excess complications. Read More ›

The Mass General Cancer Center is among the leading cancer care providers in the United States, and is a National Cancer Institute–designated comprehensive cancer center as part of the 7-member Harvard Medical School consortium. Read More ›

The largest study to date comparing outcomes of radiation therapy and postmastectomy breast reconstruction found higher rates of complication and failure in women who received radiation therapy and had implant reconstruction versus autologous reconstruction. Read More ›

Endocrine therapy is known to reduce breast cancer risk by 30% when used as primary prevention in women at risk for the disease, and the reduction lasts for at least 20 years. Read More ›

It is now widely known that light cigarettes are no safer than regular cigarettes and were only marketed in an attempt to undermine smokers’ wishes to quit smoking. According to Charlotta Pisinger, PhD, MPH, the tobacco industry is now using the same tactic with electronic cigarettes (e-cigarettes). Read More ›

Oncology professionals are routinely exposed to patient distress and trauma, and this may lead to a phenomenon called compassion fatigue. Read More ›

By improving chemotherapy-induced peripheral neuropathy (CIPN), administration of duloxetine may enable patients with advanced pancreatic cancer to continue their treatment regimen of gemcitabine plus nab-paclitaxel. Read More ›

Page 1 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: